Paper37889752
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.
Zavitsanou AM and 26 others. Cell Rep, 2023. Cited by 150 papers, by iCite.
Cite this record
ConductScience Library. KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance. Papers, record 37889752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37889752
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma of Lung | Major topic |
| Lung Neoplasms | Major topic |
| Humans | |
| Kelch-Like ECH-Associated Protein 1 | |
| NF-E2-Related Factor 2 | |
| Immune Evasion | |
| Cell Line, Tumor | |
| Mutation | |
| Immunotherapy | |
| Tumor Microenvironment |
Source PubMed
Grants13
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA271245 | NCI NIH HHS | United States | R01CA271245 | PubMed and NIH | NIH RePORTER |
| T32 CA009161 | NCI NIH HHS | United States | T32CA009161 | PubMed and NIH | NIH RePORTER |
| P01 CA229086 | NCI NIH HHS | United States | P01CA229086 | PubMed and NIH | NIH RePORTER |
| P30 CA016087 | NCI NIH HHS | United States | P30CA016087 | PubMed and NIH | NIH RePORTER |
| R01 AI143861 | NIAID NIH HHS | United States | R01AI143861 | PubMed and NIH | NIH RePORTER |
| R01 CA252239 | NCI NIH HHS | United States | R01CA252239 | PubMed and NIH | NIH RePORTER |
| R01 HL125816 | NHLBI NIH HHS | United States | R01HL125816 | PubMed and NIH | NIH RePORTER |
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed | NIH RePORTER |
| T32 AI100853 | NIAID NIH HHS | United States | T32AI100853 | PubMed and NIH | NIH RePORTER |
| R37 CA222504 | NCI NIH HHS | United States | R37CA222504 | PubMed and NIH | NIH RePORTER |
| F30 CA247020 | NCI NIH HHS | United States | F30CA247020 | PubMed and NIH | NIH RePORTER |
| T32 GM007308 | NIGMS NIH HHS | United States | T32GM007308 | PubMed and NIH | NIH RePORTER |
| R01 CA227649 | NCI NIH HHS | United States | R01CA227649 | PubMed and NIH | NIH RePORTER |
References112
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32719479 | Inducible de novo expression of neoantigens in tumor cells and mice. | Nat Biotechnol | 2021 | https://conductscience.org/library/papers/32719479 | PubMed |
| 2 | 22331464 | PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function. | Mol Cell Biol | 2012 | https://conductscience.org/library/papers/22331464 | PubMed |
| 3 | 26586766 | Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer Development. | Cancer Discov | 2016 | https://conductscience.org/library/papers/26586766 | PubMed |
| 4 | 30108253 | Keap1-MCM3 interaction is a potential coordinator of molecular machineries of antioxidant response and genomic DNA replication in metazoa. | Sci Rep | 2018 | https://conductscience.org/library/papers/30108253 | PubMed |
| 5 | 28187290 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. | Cell | 2017 | https://conductscience.org/library/papers/28187290 | PubMed |
| 6 | 28967864 | Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer. | Elife | 2017 | https://conductscience.org/library/papers/28967864 | PubMed |
| 7 | 28486109 | Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. | Cancer Cell | 2017 | https://conductscience.org/library/papers/28486109 | PubMed |
| 8 | 25337879 | Rapid modelling of cooperating genetic events in cancer through somatic genome editing. | Nature | 2014 | https://conductscience.org/library/papers/25337879 | PubMed |
| 9 | 30371878 | COSMIC: the Catalogue Of Somatic Mutations In Cancer. | Nucleic Acids Res | 2019 | https://conductscience.org/library/papers/30371878 | PubMed |
| 10 | 28967920 | Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. | Nat Med | 2017 | https://conductscience.org/library/papers/28967920 | PubMed |
| 11 | 29025772 | Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. | Cancer Discov | 2017 | https://conductscience.org/library/papers/29025772 | PubMed |
| 12 | 25818339 | Immune evasion in cancer: Mechanistic basis and therapeutic strategies. | Semin Cancer Biol | 2015 | https://conductscience.org/library/papers/25818339 | PubMed |
| 13 | 28650338 | IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. | J Clin Invest | 2017 | https://conductscience.org/library/papers/28650338 | PubMed |
| 14 | 26833127 | STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. | Cancer Res | 2016 | https://conductscience.org/library/papers/26833127 | PubMed |
| 15 | 28986418 | CD169+ macrophages orchestrate innate immune responses by regulating bacterial localization in the spleen. | Sci Immunol | 2017 | https://conductscience.org/library/papers/28986418 | PubMed |
| 16 | 28178570 | Serine Is an Essential Metabolite for Effector T Cell Expansion. | Cell Metab | 2017 | https://conductscience.org/library/papers/28178570 | PubMed |
| 17 | 32786189 | The Effect of Advances in Lung-Cancer Treatment on Population Mortality. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32786189 | PubMed |
| 18 | 21930769 | Type I interferon is selectively required by dendritic cells for immune rejection of tumors. | J Exp Med | 2011 | https://conductscience.org/library/papers/21930769 | PubMed |
| 19 | 34597124 | A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response. | Sci Immunol | 2021 | https://conductscience.org/library/papers/34597124 | PubMed |
| 20 | 15282312 | Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. | Mol Cell Biol | 2004 | https://conductscience.org/library/papers/15282312 | PubMed |
Cited by116
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 150 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42901717 | PCSK9 drives acquired resistance to anti-PD-1 immunotherapy through cystine metabolic reprogramming in lung cancer. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42901717 | PubMed |
| 42826199 | Tumor cell-intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer. | Sci Adv | 2026 | https://conductscience.org/library/papers/42826199 | PubMed |
| 42708106 | The KEAP1-NFE2L2/NRF2 Axis in Non-Small Cell Lung Cancer Radioresistance: Redox Homeostasis and Emerging DNA Damage Response Mechanisms. | Cancer Manag Res | 2026 | https://conductscience.org/library/papers/42708106 | PubMed |
| 42707968 | Adenosine signaling in tumor immune escape: metabolic checkpoints, myeloid suppression, and combination immunotherapy. | Front Oncol | 2026 | https://conductscience.org/library/papers/42707968 | PubMed |
| 42676634 | Immunotherapy plus chemotherapy improves survival in SMARCA4-deficient NSCLC: a real-world cohort study. | Front Immunol | 2026 | https://conductscience.org/library/papers/42676634 | PubMed |
| 42621827 | Gut microbiota-derived metabolites as context-dependent modulators of Nrf2 signaling in inflammation-driven carcinogenesis. | Gut Microbes | 2026 | https://conductscience.org/library/papers/42621827 | PubMed |
| 42587156 | Biomarkers of nivolumab benefit in resectable non-small cell lung cancer. | Nature | 2026 | https://conductscience.org/library/papers/42587156 | PubMed |
| 42558804 | A Glutathione Metabolism-Related Transcriptomic Signature for Prognostic Assessment and Biological Characterization of Lung Adenocarcinoma. | Cancer Inform | 2026 | https://conductscience.org/library/papers/42558804 | PubMed |
| 42519324 | Single-cell and spatial omics in non-small cell lung cancer: dissecting metabolic reprogramming and tumor-immune ecosystems for precision pharmacology. | Front Immunol | 2026 | https://conductscience.org/library/papers/42519324 | PubMed |
| 42512269 | Feasibility Study of Intratumoral NRF2 Expression as a Predictive Biomarker for the Effectiveness of Immunotherapy in Patients with Non-Small Cell Lung Cancer Treated with PD-1 Inhibitor. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42512269 | PubMed |
| 42491177 | From metabolism to genome integrity: NRF2 as a key mediator of cancer therapy response. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42491177 | PubMed |
| 42476096 | SMARCA4, STK11, and KEAP1 co-inactivation associates with poor prognosis and upregulation of the TGF-β pathway in lung adenocarcinoma. | Transl Oncol | 2026 | https://conductscience.org/library/papers/42476096 | PubMed |
| 42447505 | Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 Study. | Cancer Res Commun | 2026 | https://conductscience.org/library/papers/42447505 | PubMed |
| 42440255 | Pharmacogenomics in oncology: mutation-targeted therapy and biomarker integration in non-small cell lung cancer. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/42440255 | PubMed |
| 42435178 | Targeting Lung Cancer Metabolism: Therapeutic Opportunities and Challenges. | Adv Exp Med Biol | 2026 | https://conductscience.org/library/papers/42435178 | PubMed |
| 42426902 | Cancer stem cell plasticity: mechanisms, immune microenvironment crosstalk, and therapeutic implications. | J Hematol Oncol | 2026 | https://conductscience.org/library/papers/42426902 | PubMed |
| 42317338 | Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance. | Front Immunol | 2026 | https://conductscience.org/library/papers/42317338 | PubMed |
| 42297823 | Tumor suppressor genotype influences the extent and mode of immunosurveillance in lung cancer. | Nat Commun | 2026 | https://conductscience.org/library/papers/42297823 | PubMed |
| 42255480 | Targeting NRF2 addiction in cancer: synthetic lethal strategies beyond direct inhibition. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42255480 | PubMed |
| 42187558 | STK11 as an Emerging Biomarker in Non-Small Cell Lung Cancer. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42187558 | PubMed |
Genes29
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37889752
GET https://conductscience.org/api/papers/v1/37889752/authors?page=2